Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Trevena Inc (TRVN)

Trevena Inc (TRVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,045
  • Shares Outstanding, K 165,520
  • Annual Sales, $ 570 K
  • Annual Income, $ -51,590 K
  • 60-Month Beta 2.44
  • Price/Sales 71.70
  • Price/Cash Flow N/A
  • Price/Book 0.82
Trade TRVN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.35
  • Most Recent Earnings -0.10 on 05/11/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 554.12% ( +554.12%)
  • Historical Volatility 180.69%
  • IV Percentile 91%
  • IV Rank 41.88%
  • IV High 1,307.75% on 04/21/22
  • IV Low 10.97% on 01/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 25
  • Volume Avg (30-Day) 77
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 33,363
  • Open Int (30-Day) 32,656

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.11
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1805 +47.42%
on 05/11/22
0.3979 -33.12%
on 04/21/22
-0.1261 (-32.15%)
since 04/20/22
3-Month
0.1805 +47.42%
on 05/11/22
0.6111 -56.46%
on 03/31/22
-0.2137 (-44.54%)
since 02/18/22
52-Week
0.1805 +47.42%
on 05/11/22
2.2000 -87.90%
on 06/14/21
-1.4939 (-84.88%)
since 05/20/21

Most Recent Stories

More News
Trevena to Present at the H.C. Wainwright Global Investment Conference

CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

TRVN : 0.2661 (+8.35%)
Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of -11.11% and 96.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TRVN : 0.2661 (+8.35%)
KALA : 0.6465 (-5.14%)
Trevena Reports First Quarter 2022 Results and Provides Business Update

OLINVYK refocused commercial strategy initiated mid-Q1 OLINVYK respiratory physiology study demonstrated statistically significant reduced impact on...

TRVN : 0.2661 (+8.35%)
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

RETA : 28.78 (+3.97%)
TRVN : 0.2661 (+8.35%)
Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects

OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects Data...

TRVN : 0.2661 (+8.35%)
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund

CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

TRVN : 0.2661 (+8.35%)
OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting

CHESTERBROOK, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

TRVN : 0.2661 (+8.35%)
Trevena (TRVN) Reports Q4 Loss, Lags Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and 100.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TRVN : 0.2661 (+8.35%)
ALIM : 5.01 (+8.21%)
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group

CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

TRVN : 0.2661 (+8.35%)
Trevena Reports Fourth Quarter and Full Year 2021 Results

-- OLINVYK® utilization gaining traction in key target markets Seasoned Biopharma Leader Patricia Drake appointed new Chief Commercial Officer Topline...

TRVN : 0.2661 (+8.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of...

See More

Key Turning Points

3rd Resistance Point 0.2985
2nd Resistance Point 0.2842
1st Resistance Point 0.2752
Last Price 0.2661
1st Support Level 0.2519
2nd Support Level 0.2376
3rd Support Level 0.2286

See More

52-Week High 2.2000
Fibonacci 61.8% 1.4286
Fibonacci 50% 1.1903
Fibonacci 38.2% 0.9519
Last Price 0.2661
52-Week Low 0.1805

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar